DMAA - Drugs Made In Ameri... Stock Analysis | Stock Taper
Logo
Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA

Drugs Made In America Acquisition Corp. Ordinary Shares NASDAQ
$10.53 -0.09% (-0.01)

Market Cap $352.94 M
52w High $10.55
52w Low $10.03
P/E 0
Volume 271.91K
Outstanding Shares 33.52M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $0 $2.09M $-1.76M 0% $-0 $-2.09M
Q3-2025 $0 $263.7K $2.18M 0% $0.07 $-263.7K
Q2-2025 $0 $131.92K $2.29M 0% $0.07 $-131.92K
Q1-2025 $0 $330.93K $1.25M 0% $130.51 $-330.93K
Q4-2024 $0 $279.88 $-279 0% $-0.03 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $6.14K $239.92M $7.28M $232.64M
Q3-2025 $717 $237.63M $7.36M $230.28M
Q2-2025 $822 $235.21M $7.2M $228M
Q1-2025 $923 $232.81M $7.25M $225.56M
Q4-2024 $1.35K $550.82 $795.67 $-244

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-1.76M $-125.18K $0 $130.6K $5.42K $-125.18K
Q3-2025 $785.09K $137.91K $231.15M $-231.3M $-105 $137.9K
Q2-2025 $3.69M $-300.67K $-231.15M $231.47M $-1.27K $-300.67K
Q1-2025 $1.25M $-251.24K $-231.15M $231.4M $-428 $-251.24K
Q4-2024 $-279 $-106 $0 $-638 $-744 $-123

5-Year Trend Analysis

A comprehensive look at Drugs Made In America Acquisition Corp. Ordinary Shares's financial evolution and strategic trajectory over the past five years.

+ Strengths

DMAA’s financial structure features ample liquidity and no financial debt, limiting near-term solvency risk while it pursues a merger. Reported earnings are positive for the period, and cash levels are supported by financing inflows. Strategically, the identified target, Power Analytics, offers a well-established technology platform, deep domain expertise in mission-critical systems, and a portfolio of advanced AI and cybersecurity-related solutions that could underpin a compelling operating story post-merger.

! Risks

At present, DMAA has no revenue and negative operating and free cash flow, indicating it is not a self-sustaining business. Negative equity and retained earnings highlight accumulated losses and a fragile capital structure. The company’s future is highly dependent on a single, still non-binding merger transaction, with execution, regulatory, and timing risks. Even if the deal closes, the combined entity will face intense competition in industrial software, AI, and cybersecurity, as well as demanding regulatory and reliability expectations in its end markets.

Outlook

Near-term, DMAA’s outlook is dominated by the outcome of the de‑SPAC process rather than by its current financial performance. If the merger with Power Analytics proceeds to completion, the profile will shift from a cash shell to an operating company focused on AI-driven analytics and quantum-safe technologies for high-stakes industries. The long-term trajectory will then depend on Power Analytics’ ability to convert its technology and certifications into sustainable revenue growth, recurring cash flow, and continued innovation, all of which remain uncertain until more detailed operating data becomes available.